Johnson & Johnson Consumer France S.A.S. has entered into an agreement to acquire Biapharm SAS, a producer and marketer of skin care products centred on the leading brand Biafine.

This acquisition is subjected to customary closing conditions and regulatory approvals and is expected to be completed by the end of September. The terms were not disclosed, an official release said.

The Biapharm Group's leading brand, Biafine, is the best-known skin healing brand on the French market and is widely used as a radiotherapy burns healing product. The brand enjoys strong recognition from the medical world and is well known within French households.

The group is headed by holding company Biapharm SAS (owner of the Biafine brand) which, in turn, controls 100 per cent of Laboratoire Medix (the group's main operating company). Other products marketed by Medix include complementary skin care brands, Aloplastine and Effidia.

Johnson & Johnson Consumer France S.A.S. is a subsidiary of Johnson & Johnson.